The alternative would be induction chemotherapy followed by surgery and/or (chemo)radiation, and its efficacy and safety is being evaluated in an ongoing phase II RCT (NCT03493425) comparing upfront surgery followed by postoperative (chemo)radiation therapy to induction docetaxel and cisplatin for up to three cycles followed by surgery and postoperative (chemo)radiation therapy, which recruits paranasal sinus squamous cell carcinoma but is not limited to SMARCB1-deficient tumors [10]. The gene discussed is SMARCB1; the disease is paranasal sinus squamous cell carcinoma.